MRD Minimal Residual Disease Testing Market
MRD Minimal Residual Disease Testing Market
Scope: Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
MRD Minimal Residual Disease Testing Market Size and Growth
The Minimal Residual Disease (MRD) Testing market is experiencing significant growth, driven by advancements in technology and increasing demand for early cancer detection. The global MRD testing market is projected to reach approximately $3 billion by 2028, with a compound annual growth rate (CAGR) exceeding 10%. Rising awareness and investment in oncology propel this expansion.
Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ ICON plc
◍ ArcherDX(Invitae)
◍ ARUP Laboratories
◍ Asuragen
◍ Cergentis B.V.
◍ Bio-Rad Laboratories
◍ Mission Bio
◍ Guardant Health
◍ Invivoscribe
◍ LabCorp
◍ Inivata
◍ Natera
◍ NeoGenomics Laboratories
◍ Opko Health
◍ Quest Diagnostics
◍ Sysmex Corporation
◍ Adaptive Biotechnologies
The MRD testing market features key players like ICON plc, ArcherDX, and Natera, focusing on innovative diagnostic solutions. Companies enhance market growth through advanced technologies, clinical collaborations, and expanded testing services. Revenue examples include:
- Guardant Health: $310 million
- LabCorp: $3.1 billion
- Quest Diagnostics: $7.5 billion.
Request Sample Report
Market Segmentation
By Application
◍ Specialty Clinics and Hospitals
◍ Diagnostic Laboratories
◍ Research Institutions
By Product
◍ Flow Cytometry
◍ Polymerase Chain Reaction (PCR)
◍ Next-Generation Sequencing (NGS)
Request Sample Report
Market Growth
Request Sample Report
$ X Billion USD
